Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| fibroblast growth factors | 4804 | 162394-19-6 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
A fibroblast growth factor that is a specific mitogen for EPITHELIAL CELLS. It binds a complex of HEPARAN SULFATE and FIBROBLAST GROWTH FACTOR RECEPTOR 2B.
|
| Dose | Unit | Route |
|---|---|---|
| 4.20 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 15, 2004 | FDA | BIOVITRUM AB |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Mucosal inflammation | 47.42 | 46.01 | 17 | 331 | 49357 | 42571630 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Mucosal inflammation | 84.01 | 56.85 | 24 | 298 | 96117 | 110492860 |
None
| Source | Code | Description |
|---|---|---|
| ATC | V03AF08 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment |
| FDA CS | M0168688 | Fibroblast Growth Factor 7 |
| FDA EPC | N0000175671 | Mucocutaneous Epithelial Cell Growth Factor |
| FDA PE | N0000175675 | Increased Epithelial Proliferation |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:65023 | anti-asthmatic agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Mucositis following radiation therapy | indication | 109257007 | |
| Drug-induced mucositis | indication | 403666006 | |
| Prevention of Radiation Therapy-Induced Mucositis | indication |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Fibroblast growth factor receptor 2 | Kinase | AGONIST | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| QMS40680K6 | UNII |
| D05338 | KEGG_DRUG |
| 4024900 | VUID |
| N0000179582 | NUI |
| 4024900 | VANDF |
| C0677829 | UMLSCUI |
| CHEBI:749597 | CHEBI |
| CHEMBL1201821 | ChEMBL_ID |
| DB00039 | DRUGBANK_ID |
| D051523 | MESH_DESCRIPTOR_UI |
| 8186 | INN_ID |
| 6954 | IUPHAR_LIGAND_ID |
| 196319 | RXNORM |
| 19097 | MMSL |
| 63977 | MMSL |
| d05417 | MMSL |
| 008779 | NDDF |
| 416470008 | SNOMEDCT_US |
| 416572003 | SNOMEDCT_US |
| 417092008 | SNOMEDCT_US |
| 417550009 | SNOMEDCT_US |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| KEPIVANCE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66658-113 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 5.16 mg | INTRAVENOUS | BLA | 24 sections |